INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

(a)On May30, 2017,InVivo Therapeutics Holdings Corp. (the
Company) held its 2017 Annual Meeting of Stockholders (the Annual
Meeting). At the Annual Meeting, the Companys stockholders
approved an amendment to the Companys Articles of Incorporation
to increase the number of shares of authorized common stock from
50,000,000 to 100,000,000 shares (the Amendment). Following
stockholder approval of the Amendment, a Certificate of Amendment
to the Companys Articleof Incorporation was filed with the
Secretary of State of Nevada on June1, 2017, at which time the
Amendment became effective.

The Amendment is summarized in the Companys Proxy Statement. A
copy of the Certificate of Amendment containing the Amendment is
filed as Exhibit3.1 to this Current Report on Form8-K and
incorporated herein by reference.

Item5.07. Submission of Matters to a Vote of Security
Holders.

Set forth below are the matters submitted to the stockholders at
the Annual Meeting, all of which were approved:

the election of three (3)ClassIII directors, each to serve on the
Companys Board of Directors for a three-year term expiring at the
Companys annual meeting of stockholders in 2020 or until his or
her successor is duly elected and qualified, and one (1)ClassII
director to serve on the Companys Board of Directors for a
two-year term expiring at the Companys annual meeting of
stockholders in 2019 or until her successor is duly elected and
qualified;

the approval of the Amendment; and

the ratification of the appointment of RSM US, LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017.

The number of votes for, withheld or against and the number of
abstentions and non-votes with respect to each matter are set
forth below.

Election of Directors

ClassIII Nominees

		For		Withheld		Broker Non-Votes
Mark D. Perrin		7,960,898		1,449,133		15,374,240
C. Ann Merrifield		8,203,206		1,206,825		15,374,240
Jeffrey S. Hatfield		8,354,043		1,055,988		15,374,240

About INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV)
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI. INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Recent Trading Information
INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) closed its last trading session up +0.20 at 2.15 with 207,486 shares trading hands.